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Abstract
Background: The efficacy of the classical treatment modalities surgery and radiotherapy in the treatment of aggressive
fibromatosis is presently disputed and there is a shift towards a more conservative approach. The aim of the present
study is to objectify tumor growth in patients with extra-abdominal or abdominal wall aggressive fibromatosis, while
adhering to a “watchful waiting” policy. Other objectives are to investigate quality of life and to identify factors associated
with tumor growth, in particular the relation with the presence of a CTNNB1-gene mutation in the tumor.
Design and methods: GRAFITI is a nationwide, multicenter, prospective registration trial. All patients with extra-abdominal
or abdominal wall aggressive fibromatosis are eligible for inclusion in the study. Main exclusion criteria are: history of
familiar adenomatous polyposis, severe pain, functional impairment, life/limb threating situations in case of progressive
disease. Patients included in the study will be treated with a watchful waiting policy during a period of 5 years. Imaging
studies with ultrasound and magnetic resonance imaging scan will be performed during follow-up to monitor possible
growth: the first years every 3 months, the second year twice and the yearly. In addition patients will be asked to
complete a quality of life questionnaire on specific follow-up moments. The primary endpoint is the rate of progression
per year, defined by the Response Evaluation Criteria In Solid Tumors (RECIST). Secondary endpoints are quality of life and
the rate of influence on tumor progression for several factors, such as CTNNB1-mutations, age and localization.
Discussion: This study will provide insight in tumor behavior, the effect on quality of life and clinicopathological factors
predictive of tumor progression.
Trial registration: The GRAFITI trial is registered in the Netherlands National Trial Register (NTR), number 4714.
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Background
Biological behavior
Desmoid-type fibromatoses are rare, non-metastasizing,
locally aggressive soft tissue tumors. Aggressive fibroma-
toses can be located in every part of the body and are
classified as extra-abdominal, abdominal wall or intra-
abdominal [1, 2]. The abdominal wall is a predilection
site in women of reproductive age [3]. Sporadic onset of
the tumor is common, but an association with familiar
adenomatous polyposis (FAP) has been documented, in
particular in intra-abdominally localized aggressive fibro-
matoses [4]. The course of the disease is unpredictable
and varies between relatively indolent, i.e. stabilization of
the tumor, and progressive growth, which may halt spon-
taneously [5]. The reported frequency of recurrence fol-
lowing local treatment ranges from 5 to 63 % [6].
Genetic markers in tumor tissue have been analyzed, in
particular the CTNNB1-gene. CTNNB1-gene encodes beta-
catenin, a proto-oncogene involved in cell adhesion and cell
transcription. Beta-catenin is a key factor in the Wnt-APC-
beta-catenin pathway. On a cellular level the beta-catenin
protein level is elevated in these tumors, implicating beta-
catenin stabilization as a key factor in the pathogenesis of
aggressive fibromatosis [7, 8]. Nuclear overexpression of
beta-catenin is a histological condition used in a diagnostic.
The diagnostic value is sensitive, but not specific [8–10]. Re-
search on the CTNNB1-gene revealed 3 specific mutations,
namely T41A, S45F and 45P [8, 10]. While it is yet unclear
how these mutations precisely affect the aforementioned
pathway in these tumors, a role in biologic behavior seems
natural according to their role in pathogenesis. Several
groups have analyzed CTNNB1-mutation and these muta-
tions appear to have a prognostic value in determining the
risk of recurrence in retrospective series of surgically treated
patients [11–15]. Although Mullen et al. did not find a
statistical significant prognostic [15], several other
groups reported a higher risk of recurrence for patients
with an S45F-mutation [11–13], even in multivariate
analysis [12]. In addition, (surgical) trauma and hormones
presumably play a role in the genesis of this tumor, as
aggressive fibromatosis is known to arise in scars and in
fertile females [16].
Treatment
Treatment of aggressive fibromatosis classically in-
volves surgery, combined with radiotherapy on indi-
cation. Literature on the effects of surgery and
radiotherapy on the rate of recurrence is conflicting
[17–19]. While these effects are still being questioned,
treatment policies have recently turned towards a more
conservative approach. Nowadays, a watchful waiting
approach is being advocated by various authors and is
currently the standard in European care [20–25].
Retrospective studies showed that progression usually
occurs within 2 years of diagnosis. Fiore et al. [22] re-
ported a median time till progression of 14 months,
with 89 % of progression observed within 2 years, while
Salas et al. [18] described a median time till progres-
sion of 20 months. In addition, these studies have also
reported spontaneous regression in up to 18.5 % of the
patients [18, 22].
The ability to predict tumor behavior would enable
tailoring individual patient treatment. Little is known
about tumor growth. Available literature is dated and de-
scriptive, without objective measurements [16].
Study aim
The GRAFITI study will evaluate a watchful waiting
approach as an initial treatment for patients with extra-
abdominal or abdominal wall aggressive fibromatosis.
The primary objective is to assess tumor progression
using the Response Evaluation Criteria In Solid Tumors
(RECIST) [26]. We will attempt to identify patient-and
tumor characteristics related to growth. A twin study is
ongoing in Milan, Italy (NCT02547831). The present
study proposal was designed in collaboration with the
Italian study group, to facilitate a possible future merger
of data.
Design and methods
Study design
GRAFITI was designed in collaboration with experts in
sarcoma care throughout the Netherlands as a nationwide
prospective observational study. All patients with extra-
abdominal or abdominal wall aggressive fibromatosis are
eligible for participation. Inclusion and exclusion criteria
are discussed below. If not included, treatment options will
be discussed by the local multidisciplinary teams. Treat-
ment modalities include systemic treatment, surgery and
radiotherapy, and individualized treatment will be chosen
based on patient characteristics, tumor localization and
predicted outcome.
Patients will be treated by a watchful waiting policy
and asked to complete quality of life questionnaires.
During follow-up, imaging studies will be performed to
monitor tumor growth. In case of growth, all treatment
options will be evaluated, including continuation of
watchful waiting. A switch in treatment strategy will be
monitored and reasons for this switch documented (see
Fig. 1).
Primary objective
The primary objective is to assess tumor progression in
terms of objectifying and monitoring growth during watch-
ful waiting policy as an initial treatment. Ultrasound and
MRI imaging will be used to determine tumor size. Tumor
behavior will be scored using RECIST. Primary endpoint is
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the rate of progression per year, which will be measured
after 5 years of follow-up.
Secondary objectives
The secondary objective is to investigate the effect of
treatment on the quality of life. During the study period,
patients will be asked to complete the EORTC QLQ-C30
questionnaire five times: at inclusion and after 6,12,24 and
60 months. After a switch to active treatment, patients will
remain on-study for the questionnaires. The scores will be
evaluated and related to treatment policy.
Other objectives are to analyze the value of clinicopatho-
logical factors, including CTNNB1-gene mutation, in pre-
dicting progression. The reasons and considerations for
active treatment will be analyzed in relation to the applic-
ability of a watchful waiting policy.
Study population
The study will take place in the Netherlands. All patients
with extra-abdominal or abdominal wall aggressive fibro-
matosis are eligible for inclusion in the study. Primary and
recurrent disease will be included, stratification will be
done for analyses.
Inclusion criteria
Histological evidence of aggressive fibromatosis. Capable
to undergo MRI-scans and ultrasounds. Capable to under-
stand and sign informed consent.
Exclusion criteria
Age <18 years. Personal or family history of FAP. Intra-
abdominal tumor localization. Previous treatment for the
current manifestation (recurrent lesions without previous
treatment are included). Severe pain or functional impair-
ment due to the tumor (as indicated by the patient. The
use of painkillers is not an exclusion criterion). Tumor
progression leading to mutilation or life/limb-threatening
situations, as assessed by the attending physician.
Sample size
Based on the incidence of sporadic aggressive fibromatosis
and tumor localization, we expect to include 20 patients
annually, we aim to include 100 patients in 5 years. Loss
to follow-up or death is not to be expected. Under the
most adverse conditions, a progression rate of 50 % would
result in a 95 % confidence interval (95 % CI) of 40–60 %.
A progression rate of 25 % would result in a 95 % CI of
Fig. 1 Flowchart
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18–34 %. We consider the presented 95 % CI to be accept-
able for the study.
Methods
Participation in the study implies that the work-up does
not deviate from present common practice. A contrast
enhanced MRI-scan (T1 and T2 weighted) is used to deter-
mine the precise localization, size and involved structures.
Subsequently, and also in line with national guidelines, the
patient will undergo an ultrasound-guided, histological
needle-biopsy of the soft tissue tumor, with a 14 G needle.
Preferably 3 biopsies will be obtained. During the ultra-
sound, tumor size will be measured in three dimensions. In
addition, as part of this study a quality of life questionnaire
is completed by the patient.
The follow-up schedule is set for 9 outpatient-clinic
visits (see Table 1). During each visit imaging studies will
be performed to monitor possible growth. In addition,
patients will be asked to complete a questionnaire dur-
ing 5 follow-up visits. The radiology report of the ultra-
sound or MRI-scan will specify the maximum diameter
in all 3 dimensions and the growth in relation to previ-
ous radiological examinations. When ultrasonography
suggests tumor progression, an MRI-scan is additionally
made as standard care and considered as the golden
standard for detecting changes within the tumor.
In case of tumor progression, the patient will be re-
evaluated. If the patient is still eligible, watchful waiting
policy will be continued. If not, local or systemic treat-
ment will be started and considerations to switch treat-
ment strategies will be documented.
After inclusion of all patients, pathology specimens will
be collected by one pathology laboratory and CTNNB1-
gene analysis will be performed for all patients. If CTNNB1-
mutation status is already known, this procedure will not be
repeated.
Statistical considerations
Statistical analysis will be carried out using IBM SPSS
Statistics 21. Radiological measurements will be regis-
tered as a continuous variable at ratio. The average pro-
gression rate per year will be analyzed using data of all
patients. The progression rate per year, defined as in-
crease in size per tumor, using RECIST criteria, with the
associated range and confidence interval, will be
registered as the primary outcome. The QLQ-C30 ques-
tionnaire results in a score to classify the quality of life.
This score will be registered as discrete data at ratio
scale. If a score cannot be rewarded, the data of the
questionnaire will be regarded as missing data. If a score
is missing, but later registered scores are available, the
later scores will be used in assessment of the quality of
life. The overall quality of life will be calculated using
data of all patients at the end of follow-up. The median
value will be extracted with the associated range.
The possible influence of patient and tumor related fac-
tors on the progression rate and the quality of life are ana-
lyzed using the Kaplan-Meier method and univariable Cox-
regression. Associations between variables will be explored
by Chi-square analysis. Multivariate analysis will be per-
formed if possible by means of Cox-regression. Those fac-
tors which prove to have statistical significance in univariate
analyses, will be included in the multivariate analysis. The
considerations for treatment will be categorized and ana-
lysis will show the occurrence of specific considerations.
The interim analysis of both primary and secondary
parameters will be done after one year of follow-up on
20 patients. The analyses will be the same as described
above and will be performed by the principal investiga-
tor. For all analyses, two-sided P < 0.050 is considered
statistically significant.
Discussion
During the last decade, there has been a shift in treatment
strategy for aggressive fibromatosis from aggressive to con-
servative modalities. A watchful waiting policy is currently
advised for extra-abdominal and abdominal wall aggressive
fibromatosis [25]. Research validating the efficacy and ap-
plicability of a watchful waiting policy is limited. Mitchell et
al. were the first to describe a stable phase for aggressive
fibromatosis [5]. In a retrospective study of 17 patients
under medical observation, all experienced at least one
period of stable disease for over 6 months. A larger study
by Fiore et al. evaluated 142 patients with primary and re-
current aggressive fibromatosis, treated with initial conser-
vative treatment retrospectively [22]. Approximately 50 %
of the patients did not have tumor progression after 1 year.
Spontaneous regression has been reported by Salas et al.
[18]. In a retrospective study analyzing 426 patients with
aggressive fibromatosis, 27 patients were treated with a
Table 1 Follow-up schedule
Assessment Enrollment Year 1 Year 2 Year 3–5
Month 3 6 9 12 18 24 36 48 60
History and Physical examination x x x x x x x x x x
MRI-scan x x x x x
Ultrasound x x x x x x
QoL questionnaire x x x x x
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watchful waiting policy. Five of these patients had spontan-
eous remission, 16 patients stable disease and 6 patients
had progressive disease. The median time to progression
was 19.7 months. A recent study by Colombo et al. re-
ported 216 patients with primary extra-abdominal (n = 188)
and intra-abdominal (n = 28) disease undergoing a diversity
of treatments [24]. Initial wait-and-see policy was applied in
70 patients (60 extra-abdominal) and continued till the end
of follow-up in 60 %. Progression occurred in 16 of the 70
patients, mostly treated with systemic modalities. These re-
sults demonstrate the potential safety of a watchful waiting
policy.
Current knowledge on predictive factors is mostly
based on surgical cohorts. Age, tumor localization and
tumor size have been reported as predictive factors for
the risk of recurrence following surgery. A nomogram
was proposed by Crago et al. [27] using all these factors
in a postoperative setting.
In addition, CTNNB1-mutations are found to be a
predictive factor for the risk of recurrence following sur-
gery [12–14, 16]. The value of these factors in a postop-
erative setting cannot be extrapolated to a watchful
waiting setting. The present study was designed to
evaluate the role of these factors in relation to the pro-
gression rate in a watchful waiting setting. This informa-
tion would help in determining which patients can
safely undergo a watchful waiting policy, and which
patients would benefit most from active treatment.
The ability to predict tumor behavior would enable tai-
loring individual patient treatment and prevent over-or
undertreatment.
The low incidence of aggressive fibromatosis presents a
challenge for quality research. Collaborations between
specialized institutions is essential. The prospective evalu-
ation of predictive factors in a watchful waiting setting has
been initiated by two other research groups. In France,
Bonvalot et al. are conducting a similar study (Clinical-
Trials.gov identifier NCT01801176). They have finished
the inclusion process and are now conducting the final
follow-up. In Italy, a similar study is coordinated by Col-
ombo et al. (ClinicalTrials.gov identifier NCT02547831).
This study is still open and we encourage inclusion. The
present study was designed to resemble the French and
Italian study, to facilitate a possible merging of the data if
the inclusion rate in the studies would be disappointing.
Main inclusion and exclusion criteria match for all three
studies, though our study also includes patients presenting
with recurrent disease.
The occurrence of aggressive fibromatosis has been re-
lated to hormonal influences and pregnancy by Häyry
and Reitamo et al. [16, 28]. Although hormonal levels
and receptors on the tumor have not been investigated,
the occurrence of disease among fertile females is very
suggestive. A recent study by van Broekhoven et al.
evaluated time trends in the Dutch population [29].
Their analysis between incidence and hormonal influ-
ences did not show a positive correlation. In an attempt
to evaluate the hormonal influence, data on the use of
hormonal medication and history of pregnancy will be
collected during the present study.
Intra-abdominal tumor depositions and personal or fam-
ily history of FAP are among the exclusion criteria for the
presented study. Intra-abdominal desmoid tumors are as-
sociated with FAP [30]. This association is suggestive of a
different tumor biology compared to sporadic disease. In
addition, intra-abdominal disease is related to a high mor-
tality among FAP-patients and as such treated differently.
To limit the risks associated with the present study, these
patients are excluded from participation.
The occurrence of progression does not necessitate a
switch to active treatment. In case the safety of the pa-
tient is compromised, for example due to organ involve-
ment or increased pressure, a switch to active treatment
will be recommended. In order to minimize the risk of
compromised abilities due to tumor growth, the follow-
up schedule allows for timely detection of tumor pro-
gression and patients with vital structures at risk will not
be included in the study. The exclusion criteria prevent
life threaten of functional impairment in case of tumor
growth. Severe pain is considered to require continuous
pain medication. Active treatment does not guarantee
pain relief. As such, a watchful waiting policy should be
considered and discussed in patients experiencing de-
grees of pain. During the study period, we will monitor
the considerations in switching treatment strategies.
An interim analysis will be performed after 1 year follow-
up from the first 20 patients. This analysis is designed to
validate the safety of the study. If too many patients deviate
from the watchful waiting policy, this policy should be
questioned. Due to the benign nature of this disease, we
consider it safe if over 50 % of the patients is still undergo-
ing watchful waiting after 1 year of follow-up.
This study will provide insight in tumor behavior and
clinicopathological factors predictive of tumor progres-
sion. The ability to predict tumor behavior would enable
tailoring individual patient treatment.
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